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Protein microarray technology has been successfully used for identifying substrates of purified activated kinases.
We used protein microarrays to globally interrogate the effects of PTEN and Akt activity on the phospho-kinome of
in vitro and in vivo glioma models and validated results in clinical pathological specimens. Whole cell lysates
extracted from tumor samples can be applied to human kinome chip microarrays to profile the global kinase
phosphorylation patterns in a high-throughput manner and identify novel substrates inherent to the tumor cell and
the interactions with tumor microenvironment. Our findings identify a novel microarray-based method for
assessing intracellular signaling events applicable to human oncogenesis and other pathophysiologic states.
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Many oncogenic mechanisms are regulated through posttranslational
protein modifications, which most commonly include phosphoryla-
tion, acetylation, methylation, ubiquitination, and SUMOylation [1].
Protein phosphorylation, which is mediated by 525 annotated protein
kinases, is estimated to influence up to 30% of the proteome and
regulates fundamental cellular processes such as cell proliferation,
apoptosis, migration, and angiogenesis [1–3]. Global analyses of these
intracellular signaling networks are critical to our understanding of
oncogenesis and to the advancement of novel cancer therapeutics.
Knowledge of signaling events that drive malignancy is often
limited by experimental analyses that rely on the isolation and
assessment of singular variables. Our understanding of oncogenic
signaling networks and their contribution to cancer phenotypes
requires methodologies that globally analyze protein phosphorylation
events in cells and tissues. Protein microarray technology has been
validated previously as a tool for identifying candidate substrates of
purified kinases [4]. Hyperactivation of receptor tyrosine kinases and
their downstream effector pathways is a characteristic of multiple solid
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serine/threonine kinase that is activated through serine-473 phos-
phorylation, serves as a key node within oncogenic receptor tyrosine
kinase signaling networks. Akt hyperactivation commonly results
from loss of function of the tumor-suppressing dual-specificity
phosphatase PTEN, which is commonly mutated or deleted in solid
malignancies including 40% to 50% of glioblastomas. Activating Akt
mutations have been found in 22% to 87% of solid malignancies and
up to 54% of gliomas [5]. Here we describe the novel application of
protein microarray technology to globally assess the influence of
PTEN function on the phospho-kinome of glioma cells in vitro and
glioma xenografts in vivo. Specifically, we used a tet-inducible systemFigure 1. (A) Immunoblot analysis of PTENexpression and phospho-Akt
(B) MTT analysis of U87 glioma cell +/− Doxy demonstrates decreas
(C) U87 glioma xenografts +/− Doxy demonstrate decreased tumor
paradigm used to evaluate effect of PTEN reconstitution (control versu
microarrays. (E) Whole cell lysates from U87 glioma cells +/− Doxy a
analyzed on human kinase microarrays with magnified representati
response to doxycycline.to investigate how Akt deactivation, as a downstream consequence of
PTEN reconstitution, regulates known and novel protein substrates
implicated in glioma malignancy. This global analysis identifies a
novel microarray-based method for assessing intracellular signaling
events underlying human oncogenesis.
Results
We asked if protein microarray technology, similar to that previously
developed for the evaluation of substrates of purified kinases, can be
used to analyze more complex and biochemically heterogeneous cells
and tissues toward the goal of understanding complex cell signaling
cascades, such as those associated with oncogenic signal regulationlevels inU87glioma cells+/−PTEN-reconstitution (Doxycycline/Doxy).
ed cell growth in U87 cells in response to PTEN induction by Doxy.
growth in response to PTEN induction by Doxy. (D) Experimental
s experimental) on the U87 glioma cell kinome using human protein
nd (F) whole tissue lysates from U87 glioma xenografts +/− Doxy
ve section demonstrating decreased substrate phosphorylation in
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phosphorylation events in response to incubating protein microarrays
with control whole cell lysates were optimized by varying the
concentrations of whole cell lysate protein and time of incubation on
the microarrays. HEK93 cell lysates were diluted to achieve final protein
concentrations ranging from 0 to 0.8 μg/μl and then incubated on protein
microarrays in the presence of 32P-γ-ATP for 0, 10, 30, 60, and 120
minutes as previously described with modifications [3,4] (Supplemental
Figure 1). Reactions were terminated by washing microarrays with
Tris-buffered saline (TBS) containing 0.1% Tween 20 (TBS/T) and SDS
buffers to ensure that the radioactivity detected on the arrays was due to
covalent phosphorylation, and phosphorylation signals were then
visualized by autoradiography and analyzed using the GenePixFigure 2. Identification and confirmation of PTEN-regulated kinase sub
glioma cells (in vitro; left panel) and glioma xenografts (in vivo; right
P value significance. Venn diagram shows the number of PTEN-reg
microarray. (B) Immunoblot of 20 primary human GBM samples st
(p-Akthigh and p-Aktlow) showing phosphorylated forms of candidate k
levels of phospho-CDK2, phospho-CDC2, phospho-PAK4, phospho-ssoftware as described in Materials and Methods. All experiments were
carried out using optimized conditions (0.2 μg/μl of lysate concentration
and 30-minute incubation time) (Supplemental Figure 2).
Human U87 glioma cells, engineered to express PTEN via a tet-on
promoter system (U87-tetPTEN), were used to examine the global
effects of PTEN reconstitution on the cell phospho-kinome [6]. We
quantified the effects of doxycycline on the induction of PTEN and
Akt phosphorylation (Ser473) and the biological response of glioma
cell growth in vitro and tumor xenograft growth in vivo. PTEN was
robustly increased, and Akt phosphorylation was inhibited by ~90%
(P b .05) after incubating cells with doxycycline for 24 hours
(Figure 1B). PTEN reconstitution in vitro inhibited cell growth by
~70% (Figure 1B), and treating animals following cell implantationstrates. (A) Volcano plot analyses of results obtained from cultured
panel) identified substrates organized by fold-change intensity and
ulated phosphorylated substrates identified via the human protein
ratified based on high and low phospho-Akt (Ser473) expression
inase substrates identified by microarray. (C) Scatter plots of relative
6R, and phospho-Lyn in p-Akthigh and p-Aktlow clinical gliomas.
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xenografts, which were ~60% smaller than controls on posttreatment
day 6 (P b .05) (Figure 1C). These cell and tumor xenograft responses
are consistent with PTEN’s known signaling and tumor-suppressive
biological activities and establish the conditions for using this model
to study global effects of PTEN on the glioma cell phospho-kinome.
Whole cell (in vitro) or whole tumor (in vivo) lysates obtained
from control and doxycycline-treated conditions were incubated on
human protein microarrays in the presence of 32P-γ-ATP at 30°C,
and microarrays were processed essentially as described in Materials
and Methods and depicted in Figure 1, D–F. Partek software was
used to analyze and compare the number and relative intensity of
protein phosphorylation events on the microarrays. Figure 2A
(left and right panels) depicts the fold-change by volcano plot for all
phosphorylation events from in vitro and in vivo lysates, and the
Venn diagram (middle panel) demonstrates the number of distinct
and common in vitro and in vivo phosphorylation events. PTEN
reconstitution in vitro decreased the phosphorylation of 36, 103, and
135 protein targets using P b .05, P b .15, and P b .20, respectively,
as statistical cutoffs (Supplementary Table 1). This analysis identified
phospho-ribosomal S6 kinase polypeptide and phospho-CDC2, two
differentially phosphorylated targets that are known to regulate cell
cycle progression at the G2/M checkpoint (see Supplemental
Material), as well as the second messenger molecules MAPK and
Akt. Immunoblot analyses of control and doxycycline-treated
U87-tetPTEN cell lysates confirmed that PTEN induction reduced
endogenous phospho-ribosomal S6 kinase polypeptide by ~95% (P b
.05) and phospho-CDC2 by ~50% (P b .05) (Supplementary Figure 3).
PTEN induction in vivo reduced the phosphorylation of 16, 67, and 103
microarray protein targets at P b .05, P b .15, and P b .20 statistical
cutoffs, respectively (Supplementary Table 2). Similar to the in vitro
results, the in vivo analysis identified phospho-ribosomal S6 kinase
polypeptide, MAPK, Akt, and phospho-CDK2 (Table 1). Immunoblot
analyses of tumor lysates confirmed that PTEN induction inhibited the
phosphorylation of endogenous ribosomal S6 kinase by ~65%, CDK2
by ~50%, PAK4 by ~65%, and MAPK by ~55% (P b .05), validating
the ability of protein microarrays to predict phospho-kinome dynamics
ex vivo (Supplemental Figure 3).
Akt is one of the most proximal downstream effectors of PTEN
reconstitution predicting that the PTEN-regulated phospho-proteins
identified by microarray analysis would correlate with the phosphor-
ylation status of AKT in clinical tumor specimens. Twenty clinical
WHO grade IV gliomas were obtained and stratified by semiquan-
titative immunoblot analysis into high phospho-Akt expressers and
low phospho-Akt expressers. The 10 clinical specimens that expressedTable 1. Overlapping In Vitro and In Vivo Substrate List
Column ID
ADRBK2 His-Avi PRKACA
AURKC ILK PRKACB
C9orf96 LYK5 RPS6KA4
CAMK2A LYN SRPK2
CCL2 MAP2K4 SYK
CDC2 MAP3K7 TBK1
CDK2 MAPK11 TRIM27
CDKN1A MAPK13 TTBK2
CSNK2A1 MAPKAPK5 WIF1
DAPK2 NRP2 XRCC6BP1
DCLK1 PDGFRL ZAP70
H2B (100ug/ml) PKB/AKT com rrnL2athe highest levels of phospho-Akt using the Odyssey Infared Imager
(LI-COR Biosciences) were placed in the “high phospho-Akt
expressers,” and the remaining clinical specimens were placed in the
“low phospho-Akt expressers.” We then analyzed tumor lysates by
immunoblot for five phospho-proteins shown to be PTEN-regulated
(in vitro or in vivo) by the protein microarray assays described above.
The five candidate phospho-proteins were chosen based on their
known function as regulators of cell growth and/or cell cycle
progression and antibody availability. As predicted by microarray,
the low–phospho-Akt glioblastomas had statistically significantly
lower phosphorylated forms of these five phospho-proteins than
the high–phospho-Akt glioblastomas (Figure 2, B and C).
Specifically, phospho-CDK2 was reduced by ~85%, phospho-CDC2
by ~90%, phospho- ribosomal S6 kinase polypeptide by ~70%,
phospho-PAK4 by ~80%, and phospho-Lyn by ~70% in low–
phospho-Akt specimens. Thus, microarray analysis correctly predicted
associations between Akt activity and protein phosphorylation status in
clinical specimens.
Discussion
In conclusion, we show that the human kinase protein microarrays
offer an effective high-throughput platform to profile global kinase
phosphorylation patterns in lysates obtained from whole cells and
tissues. This methodology does not rely on the availability or
specificity of antibodies or other types of affinity reagents, which can
be problematic. Compared with tandem mass spectrometry
approaches, this microarray technique offers cost-effectiveness and
exceedingly high throughput for generating an activity-based profile
of the human kinome in complex biological systems. The in vitro and
in vivo glioma models used in this study generated overlapping but
distinct phospho-protein patterns. These differences can be attributed
to any of the many characteristics that differentiate the two model
systems including but not limited to tumor microenvironment effects
and stromal cells in the more complex tumor xenografts. Traditional
immunoblot analysis of clinical glioma specimens for candidate
phospho-protein substrates identified in preclinical glioma models by
microarray validated the predictive value of the protein microarray
method. Human protein microarray technology offers a new
high-throughput method for performing unbiased global analyses of
intracellular signaling networks underlying malignancy and other
pathologic processes.
Materials and Methods
Human Open Reading Frame (ORF) Cloning
Using the Gateway recombinant cloning system (Invitrogen, CA),
human ORFs were shuttled from the selected entry clones of the
Ultimate Human ORF Collection (Invitrogen, CA) to a yeast
high-copy expression vector (pEGH-A) that produces 6x-His-GST
fusion proteins under the control of the galactose-inducible GAL1
promoter [4]. Plasmids were rescued into Escherichia coli and verified
by restriction endonuclease digestion. Plasmids with inserts of correct
size were transformed into yeast for protein purification (see
Supplementary Information).
Protein Purification and Proteome Arrays
The human kinase proteins were purified as 6x-His-GST fusion
proteins from yeast using a high-throughput protein purification
protocol similar to that described previously [7]. Human kinome
protein microarrays were custom-made slides and subjected to
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chip using previously established protocols [3,4]. In brief, about 520
yeast strains that consistently overexpress yeast proteins as GST
fusions were used to prepare protein chips. GST fusion proteins were
bound to glutathione beads (GE Healthcare) for 1 hour at 4°C,
washed four times with wash buffer I (50 mM Tris–HCl [pH 7.5],
500 mM NaCl, 1 mM EGTA, 10% glycerol, 0.1% Triton X-100,
0.1% β-mercaptoethanol, and 0.5 mM PMSF) and two times with
wash buffer II (50 mM HEPES [pH 7.4], 100 mM NaCl, 1 mM
EGTA, 10% glycerol, 0.1% β-mercaptoethanol, and 0.5 mM
PMSF), and eluted in elution buffer (50 mM HEPES [pH 7.4],
100 mM NaCl, 40 mM reduced glutathione, 0.03% Triton X-100,
and 30% glycerol). Each kinase protein was assayed by in vitro dot
blot by incubating at 30°C for 30 minutes in the presence of kinase
buffer, and the reaction was terminated by heating the mixture at
90°C for 5 minutes. The majority of the proteins were not able to
autophosphorylate under these conditions. Protein products that were
successfully purified based on immunoblot analysis were then spotted in
duplicate onto surface-modified glass (Full Moon Biosystems)
microscope slides using a 48-pin contact printer (Bio-Rad).
Elimination of Printing Bias
Multiple array comparisons were critical for optimizing the
dynamic kinase assays performed on the protein microarrays. To
ensure the equality of the arrays used to perform the dynamic kinase
assays, the signal intensities of each protein coordinate were required
to be greater than the threshold on all anti-GST arrays. Taking into
consideration the signal intensity of each protein coordinate
imprinted on the anti-GST X scan of each microarray, only proteins
on the anti-GST microarrays with Z score N3 were used for further
analyses. Positive and negative control proteins (i.e., BSA and
histones) were excluded from the analyses.
Phosphorylation Assay and Data acquisition
Cell lysate samples were assayed to determine the protein
concentration needed to achieve optimal signal:noise ratio using
test protein chips (see Supplementary Information). Proteome arrays
were blocked in 1× TBST containing 0.1% BSA (Roche) for 30
minutes at 30°C with gentle shaking. Lysates were diluted into kinase
buffer (50 mM Tris–HCl [pH 7.5], 100 mMNaCl, 10 mM, MgCl2,
1 mM MnCl2, 1 mM DTT, 1 mM EGTA, 25 mM Hepes-KOH
[pH 7.5], 2 mM NaVO4, 2 mM NaF, 0.01% cold ATP, and
γ-32P-ATP [33.3 nM final concentration]) and incubated on
cover-slipped arrays in a humidified chamber at 30°C for 30 minutes
in triplicate (see Lysate Methods in Supplemental Information). The
arrays were subjected to three 10-minute washes in 1× TBST (pH
7.5), three 10-minute washes in 0.5% SDS, and one quick rinse with
distilled water before spin drying and X-ray film (Kodak) exposure.
Control arrays were incubated with kinase reaction mixture without
protein lysate and processed in parallel. Three sets of exposures were
taken for each kinase assayed: 10, 17, and 24 hours. The X-ray film
was scanned at 4800 dots per inch and analyzed using Genepix 3.0
(Molecular Devices). The optimal exposure was selected for each set
of experiments and compared with the corresponding control slides.
Identification of Positive Hits
For the microarray analysis of both in vitro cell models and in vivo
xenografts, a ΔZ score (representing the Z-score difference between
treatment and control experimental arrays) was calculated for eachprotein represented on the microarray. For the selected ΔZ cutoff, Z0,
we obtained a number of differentially phosphorylated proteins,
H(Z0), and calculated corresponding P values. To determine an
optimal cutoff, we calculated an enrichment score using
En ¼
H Z0ð Þ
nH
P Z0ð Þ
nP
where P(Z0) is number of all differentially phosphorylated proteins
under the cutoff Z0, and nH and nP are total numbers of proteins and
all proteins on the chip, respectively. The final ΔZ cutoffs were then
optimized by the maximum enrichment score recovered.
Background Correction and Normalization of
Protein Microarrays
The raw signal intensity of each array coordinate corresponding to
immobilized protein was defined as the foreground median intensity
divided by its local background median intensity as acquired using the
GenePix software. More than 1000 “empty” or “blank” coordinates
on each microarray were used to assess background signal intensities.
Our analyses showed that the distribution of raw signal intensities of
all “blank” coordinates on an array approximated a normal
distribution with the mean value around 1. Assuming that the raw
intensity distributions of these “blank” coordinates (background
noises) were the same across all microarrays (under different
conditions), we used a Z-score to set a universal background cutoff
for all conditions. Hence, the protein signals were standardized using
Z Ið Þ ¼ I−m
r
where Z is Z-score of each protein coordinate, I is raw intensity of the
coordinate, and m and σ are mean value and standard deviation,
respectively, of “blank” coordinates on the microarray.
Data Analysis
A mixed-model analysis of variance was used to detect differential
phosphorylation for each immobilized protein substrate using Partek
software [8]. To assess differential protein phosphorylation for each of
the lysate preparations, we first averaged all kinases from a particular
experimental group. Substrates on the human kinome chip were
assigned to one or more functional groups with a unique ID number
based upon GO annotations [9–11]. To assess the statistical
significance of phosphorylation differences, we implemented a t test
procedure, which defines phosphorylation as either regulated or not,
and employed a Fisher's exact test or hypergeometric distribution
analysis. Under the usual assumptions, namely, independence and
normality of the error, a t test offers more power than a test with a
dichotomized outcome.
Clinical Specimens and Cell Culture
Human clinical specimens were obtained from the Johns Hopkins
Neurosurgical operating suites. The Johns Hopkins University
Institutional Review Board approved all protocols in this study.
The tet-on PTENwt-inducible U87 cell line was a kind gift from
Dr. Maria Georgescou (MD Anderson Cancer Center) and cultured
as previously described [6,12]. The tetracycline-inducible PTENwt-
expressing cell line was developed using a retroviral vector in the
PTEN-deficient U87 glioma cell line. Two retroviral constructs,
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simultaneously introduced to U87 glioma cells by infection. The
pCXn/TR2 construct encodes TR of the tetracycline operon
that is found in the second construct. The second pCXbR(TO)-
PTEN construct contains the inducible promoter that controls
transcription of wild-type PTEN. When tetracycline, or its derivative
doxycycline, is present, the repressor is inhibited and catalytically
active PTEN is expressed. When tetracycline, or its derivative
doxycycline, is absent, the repressor prevents PTEN expression from
the second retroviral construct.
Whole Cell Lysate Preparation
Total protein was extracted from glioma xenografts and cells using
radioimmunoprecipitation assay buffer (1% Igepal, 0.5% sodium
deoxycholate, and 0.05% SDS in PBS) containing fresh 1× protease
and 1× phosphatase inhibitors (Calbiochem) at 4°C. Tissue extracts
were sonicated on ice and centrifuged at 5000 rpm at 4°C for 5
minutes. Supernatants were assayed for protein concentrations by
Coomassie protein assay (Pierce) according the manufacturer's
recommendations.
Immunoblot analysis
Aliquots of 40 or 60 μg of total protein were combined with
Laemmli loading buffer containing β-mercaptoethanol and subjected
to SDS polyacrylamide gel electrophoresis according to the method of
Towbin et al. with some modifications [13,14]. For immunoblot
analyses, proteins were electrophoretically transferred to nitrocellulose
with a semidry transfer apparatus (GE Healthcare) at 50 mA for 60
minutes. Membranes were incubated for 1 hour in Odyssey Licor
Blocking Buffer at room temperature and then overnight with
primary antibodies at 4°C in 5% BSA in TBS/T. Membranes were
then washed 3× with TBS/T, incubated with secondary antibody at
1:10,000 for 1 hour in TBS/T, and washed 3× with TBS/T, followed
by washing 2× with TBS. Proteins were detected and quantified using
the Odyssey Infrared Imager (LI-COR Biosciences).
Cell Viability Assay
Cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) assay as previously reported
[13]. Cells were plated at 50,000 cells/well in 24-well tissue culture
plates and cultured for 24 hours before treatment with specified
reagents. Twenty-four to 72 hours after treatment, MTT was added
to each well at a final concentration of 150 μg/ml, and the cells were
incubated for 2 hours at 37°C. The medium was then removed, and
the cell layer was dissolved with dimethyl sulfoxide. The formazen
reaction product was quantified spectrophotometrically at 570 nm
using a Spectra MAX 340pc plate reader (Molecular Devices,
Sunnyvale, CA). Results are expressed as the percentage of absorbance
measured in control cultures after subtracting the background
absorbance from all values.
Tumor Xenografts
Glioma xenografts were generated as previously described [15]. Female
6- to 8-week-old mice (National Cancer Institute, Frederick, MD) were
anesthetized by intraperitoneal injection of ketamine (100 mg/kg) and
xylazine (5 mg/kg). For subcutaneous xenografts, Nu/nu mice received
4 × 106 cells in 0.05 ml of plain media subcutaneously in the dorsal
flank. When tumors reached ~200 mm3, the mice were randomly
divided into groups (n = 5 per group) and received the indicated doses ofeither 5% sucrose or 5% sucrose + 2 μg/ml of doxycycline in the
drinking water as previously described [6]. Tumor volumes were
estimated by measuring two dimensions [length (a) and width (b)] and
calculating volume asV = ab2/2 [16,17]. At the end of each experiment,
tumors were excised and frozen in liquid nitrogen, and protein was
extracted for immunoblot analysis.
The Johns Hopkins University Institutional Animal Care and Use
Committee approved all animal protocols used in this study. All experiments
were performed in accordance with relevant guidelines and regulations.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2016.02.001.
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